55results about How to "Lower dose level" patented technology

A method for inhibiting formation of hydrocarbon hydrates in mixtures of water and a hydrate-forming guest molecule involves adding an ion pair to the mixtures in an amount effective to inhibit formation of the hydrocarbon hydrates under conditions otherwise effective to form the hydrocarbon hydrates in the absence of the ion pair. In one non-limiting embodiment of the invention the ion pair includes a cationic component that may be a quaternary ammonium compound or an onium compound and a non-cationic counter-ion component that could be an anionic compound, a non-ionic compound and / or an amphoteric compound. Two specific, suitable non-cationic counter-ion components include sodium dodecyl sulfate and ammonium alkyl ether sulfate.

The present invention discloses compounds according to Formula I:Wherein R1a, R1b, R2, R4, R5, R6a, R6b, R7, R8, W, X, Cy, and the subscript a are as defined herein.The present invention relates to compounds inhibiting autotaxin (NPP2 or ENPP2), methods for their production, pharmaceutical compositions comprising the same, and methods of treatment using the same, for the prophylaxis and / or treatment of diseases involving fibrotic diseases, proliferative diseases, inflammatory diseases, autoimmune diseases, respiratory diseases, cardiovascular diseases, neurodegenerative diseases, dermatological disorders, and / or abnormal angiogenesis associated diseases by administering the compound of the invention.

A method and system are providing for performing X-ray diagnostic imaging using a camera image controlled to image a field of view (FOV) that is substantially coincident and coplanar with a radiation footprint or FOV of an X-ray beam radiated towards a patient under examination. Both the X-ray beam and camera FOVs are shaped and / or limited by collimation. The method and system include acquiring a camera image with a collimated FOV to an X-ray beam FOV before X-ray imaging a patient, displaying the camera image and adjusting the collimation and patient positioning to define the X-ray beam FOV based on the displayed camera image before X-ray imaging the patient. After adjustment, the method and system include radiating the X-ray beam as collimated during the patient X-ray imaging, acquiring and processing captured X-ray image information to reconstruct an X-ray image and displaying the reconstructed X-ray image with the displayed camera image. The step of radiating may be postponed or interrupted for X-ray beam readjustment or patient repositioning for desired X-ray imaging based on the camera image displayed.

The present invention includes systems and methods for decreasing the pain and discomfort commonly associated with endoscopic procedures, where such procedures may be performed with lower dosage levels of sedative and analgesic drugs. The invention includes use of an anesthetic collar coupled to an endoscope with a flexible shaft. The anesthetic collar allows lubricants, local anesthetics, dyes, and / or other desirable fluids to be passed through the existing lumen of the flexible shaft into an annulus, where the fluid may be distributed through expulsion pores into the gastrointestinal tract. Utilizing the existing lumens found in endoscopes, the present invention allows those fluids that may reduce the pain and discomfort associated with endoscopies such as, for example, local anesthetics and lubricants, to be distributed in an even fashion throughout the gastrointestinal tract or throughout the length and circumference of the endoscope, where such fluids may reduce the drug level requirements for sedative and analgesic agents. Alternatively, the endoscope may be redesigned for streamlined integration with the anesthetic collar or to accomplish the same function of distributing local anesthetics and lubricants, in an even fashion throughout the gastrointestinal tract or throughout the length and circumference of the endoscope, The invention can also be used with endoscopes without existing lumens.

The present invention is drawn to methods for photodynamic therapy (PDT) of a target cell, target tissue or target composition in a mammalian subject, using a therapeutically effective amount of a targeted substance, which is either a targeted photosensitizing agent, or a photosensitizing agent delivery system, or a targeted prodrug. This targeted substance preferably selectively binds to the target cell, target tissue or target composition. Light at a wavelength or waveband corresponding to that which is absorbed by the targeted substance is then administered. The light intensity is relatively low, but a high total fluence is employed to ensure the activation of the targeted photosensitizing agent or targeted prodrug product.

A method and system are providing for performing X-ray diagnostic imaging using a camera image controlled to image a field of view (FOV) that is substantially coincident and coplanar with a radiation footprint or FOV of an X-ray beam radiated towards a patient under examination. Both the X-ray beam and camera FOVs are shaped and / or limited by collimation. The method and system include acquiring a camera image with a collimated FOV to an X-ray beam FOV before X-ray imaging a patient, displaying the camera image and adjusting the collimation and patient positioning to define the X-ray beam FOV based on the displayed camera image before X-ray imaging the patient. After adjustment, the method and system include radiating the X-ray beam as collimated during the patient X-ray imaging, acquiring and processing captured X-ray image information to reconstruct an X-ray image and displaying the reconstructed X-ray image with the displayed camera image. The step of radiating may be postponed or interrupted for X-ray beam readjustment or patient repositioning for desired X-ray imaging based on the camera image displayed.

The invention discloses a neutron moisture gauge detector which comprises a housing, a cadmium plate layer wrapped on the outer wall of the housing and a neutron source arranged at a vertical center of the cavity of the housing, wherein a back reflection plate closely connected with the inner wall of the housing and the outer wall of the neutron source is horizontally arranged in the cavity of the housing, an electronics unit mainly composed by a high voltage module and a signal processing module is arranged at the bottom of the cavity of the housing, residual space in the cavity of the housing below the back reflection plate is filled with shielding layers, a plurality of sets of counting tube supports symmetrically arranged from interior to exterior and counting tubes installed on the supports are arranged around the head of the neutron source in space in the housing above the back reflection plate, the root parts of the supports are fixed on the back reflection plate, the counting tubes are installed to form a rectangular array, the height of the counting tubes on the supports gradually increases from interior to exterior to form ladder distribution, an inclined plane reflection plate in a loop corridor is arranged around the counting tubes on the supports, the sidewall of the inclined plane reflection plate is fixed on the sidewall of the housing, and the bottom of the inclined plane reflection plate is fixed on the back reflection plate. The neutron moisture gauge detector provided by the invention has the advantages of good sensitivity, high usage efficiency of the neutron source and the like.

The present invention discloses compounds according to Formula I:Wherein R1a, R1b, R2, R4, R5, R6a, R6b, R7, R8, W, X, Cy, and the subscript a are as defined herein. The present invention relates to compounds inhibiting autotaxin (NPP2 or ENPP2), methods for their production, pharmaceutical compositions comprising the same, and methods of treatment using the same, for the prophylaxis and / or treatment of diseases involving fibrotic diseases, proliferative diseases, inflammatory diseases, autoimmune diseases, respiratory diseases, cardiovascular diseases, neurodegenerative diseases, dermatological disorders, and / or abnormal angiogenesis associated diseases by administering the compound of the invention.

The present invention discloses compounds according to Formula I:Wherein R1a, R1b, R2, R4, R5, R6a, R6b, R7, R8, W, X, Cy, and the subscript a are as defined herein. The present invention relates to compounds inhibiting autotaxin (NPP2 or ENPP2), methods for their production, pharmaceutical compositions comprising the same, and methods of treatment using the same, for the prophylaxis and / or treatment of diseases involving fibrotic diseases, proliferative diseases, inflammatory diseases, autoimmune diseases, respiratory diseases, cardiovascular diseases, neurodegenerative diseases, dermatological disorders, and / or abnormal angiogenesis associated diseases by administering the compound of the invention.

The present invention discloses salts of a Compound 1:useful in the prophylaxis and / or treatment of inflammatory conditions, autoimmune diseases, proliferative diseases, allergy, transplant rejection, diseases involving degradation and / or disruption of cartilage homeostasis, congenital cartilage malformations, and / or diseases associated with hypersecretion of IL6 or interferons.

The present invention relates to an implantable drug delivery device comprising a polymeric or polymeric containing material in combination with a therapeutic compound effective for the treatment of a member of the herpesvirus family, wherein the therapeutic compound is in an amount that will effectively treat HSV-1, HSV 2 and / or VZV or reduce reactivation, and wherein the implantable drug delivery device is positioned at or near the site of latent infection or at the site of observed clinical symptoms. The therapeutic compound may include any active antiherpes agent including acyclovir, guanosine, valacyclovir or functionally active analogues.

The invention relates to a reactor pressure vessel simulation test platform for a nuclear power plant. The reactor pressure vessel simulation test platform comprises a test platform base, a plurality of test platform support upright columns whose bottom ends are fixed to the test platform base, a pressure vessel simulation flange fixed to the top ends of the test platform support upright columns, a personnel operation platform fixed to the test platform support upright columns through an oblique support, a test platform crosspiece which is fixed among the test platform support upright columns and has an upper layer, a middle layer and a lower layer, a test platform ladder respectively fixed to the test platform base and the test platform crosspiece, a simulation pressure vessel cylinder wall vertical plate fixed to neighboring layers of the test platform crosspiece, and a test platform simulation pool fixed on the test platform base. The reactor pressure vessel simulation test platform can be installed in a proper workshop outside a reactor containment vessel in a nuclear power plant area. Before a set is shut down and the maintenance work begins, debugging, verifying of special-purpose tools and personnel training work can be finished.

A uterine fibroid treatment device providing for localized delivery of one or more treatment drugs for treating various uterine conditions including, for example, uterine fibroids, abnormal uterine bleeding, pelvic adhesions and endometriosis. Generally, the uterine treatment device comprises a physical positioning element that can be inserted, positioned and maintained in close proximity to the uterine tissue to be treated. The treatment drugs delivered to the treatment location can include various combinations of anti-proliferative agents and angiogenesis inhibitors to provide different treatments concurrently. In some embodiments, the physical element can also serve the dual purpose of delivering the treatment drugs while simultaneously cutting off blood flow to a mature fibroid to initiate hypoxic / ischemic conditions within the mature fibroid.

The invention discloses a floating nuclear power station reactor compartment arrangement structure which comprises a double-shell ship body arranged on an offshore nuclear power platform, wherein a primary containment vessel and a spent fuel storage cabin are arranged in an inner cavity of the double-shell ship body; a reactor and primary loop system equipment are arranged in the primary containment vessel; a spent fuel storage facility is arranged in the spent fuel storage cabin; the bottoms and the side faces of the primary containment and the spent fuel storage cabin are elastically connected with the double-shell ship body through elastic connecting structures; a nuclear fuel loading and unloading cabin is arranged on the upper portions of the primary containment and the spent fuel storage cabin; and communication ports are formed between the nuclear fuel loading and unloading cabin and the primary containment and between the nuclear fuel loading and unloading cabin and the spent fuel storage cabin respectively. The nuclear fuel tank has three functions of containment, nuclear fuel loading and unloading and spent fuel storage, and has the characteristics of regular appearance,compact layout, low design pressure and light shielding weight; and an elastic connecting structure is provided, so that the safety of the reactor cabin is further improved.

The present invention provides a risk evaluation method for prolong a test cycle of a containment in a nuclear power plant. The method comprises the following steps of: S101, obtaining a quantitativeanalysis result of an early-phase radioactivity release sequence according to a nuclear power plant first-level probability safety evaluation analysis result, and according to an accident type, employing a containment even tree to perform classification of the containment state corresponding to the final state of the early-phase radioactivity release sequence; S102, determining a population dosagereference value corresponding to each accident class; S103, determining a lot of early-phase radioactivity large dosage release frequency increment [Delta]LERF, an index population dosage increment rate [Delta]Dose, and the containment generation probability CCFP (Conditional Containment Failure Probability) and a change [Delta]CCFP thereof when the reactor core damaging accident is generated; S104, according to the [Delta]LERF, the [Delta]Dose, the CCFP and the [Delta]CCFP, analyzing a risk after the containment sealing test cycle is changed through a preset corresponding reference value; and S200, according to an analysis result obtained the steps mentioned above, outputting evaluation result.

The use is provided of a calcitonin in the preparation of a medicament for the treatment of an inflammatory disease or condition. The calcitonin may be selected from the group consisting of human, salmon, eel, porcine, bovine, or chicken calcitonin or a derivative, a fragment or a variant thereof. The inflammatory disease or condition may be rheumatoid arthritis (RA), juvenile rheumatoid arthritis (JRA), osteoarthritis, psoriasis, psoriatic arthritis, ankylosing spondylitis (AS), lupus erythamatosis, multiple sclerosis (MS), asthma, or immuno-suppressive therapy (e.g. post transplantation surgery). The treatment may also comprise administration of a glucocorticoid, an anti-rheumatic drug or an antibody.

The present invention provides a specific binding molecule that binds to Annexin-1 (Anx-A1) for use in the treatment of obsessive compulsive disorder (OCD) or a disease related to OCD. The invention also provides a pharmaceutical composition comprising a specific binding molecule of the invention for use in the treatment of obsessive compulsive disorder (OCD) or a disease related to OCD.

A pharmaceutical composition, and methods for using a pharmaceutical composition, for treating osteoarthritis in a subject in need thereof, the pharmaceutical composition including cannabidiol or a pharmaceutically acceptable salt thereof; and especially wherein administration of the cannabidiol is by a transdermal pharmaceutical gel composition. A method is disclosed for treating one or more symptoms of osteoarthritis in a patient. The method includes transdermally administering an effective amount of cannabidiol (CBD) to the patient wherein one or more symptoms of osteoarthritis are treated in the patient.

Provided herein is a pharmaceutical composition comprising (i) a phosphodiesterase inhibitor or an adenosine receptor antagonist, (ii) a calcium channel blocker, (iii) a histamine H1-receptor agonist, a histamine H2-receptor agonist, or a histamine H3-receptor antagonist, and (iv) a β2-adrenoreceptor agonist; wherein at least one of two or more active pharmaceutical compounds is deuterium enriched. Also provided herein is a pharmaceutical composition comprising at least one of two or more deuterated compounds which increase pharmacokinetic half-life (increasing the duration of action) and reduce side effects by allowing for reduction of the dose levels. A method of use thereof pharmaceutical composition for treating, preventing, or ameliorating a cardiovascular disease.

A system and method for sterilization of medical devices includes methods for reducing the variance in dose levels over the medical device by either varying the dose levels for each pass before a radiation source, such as an electron beam, or by increasing the number of passes before a radiation source.

The present invention provides a method for providing latency to a pharmaceutically active agent. The method has application in overcoming the toxic effect of systemic administration of potent biological agents. The method comprises associating a fusion protein comprising a latency associated peptide and a proteolytic cleavage site with a pharmaceutically active agent. The fusion protein also has application in providing site specific activation to a latent pharmaceutically active agent.

A system and method for sterilization of medical devices includes methods for reducing the variance in dose levels over the medical device by either varying the dose levels for each pass before a radiation source, such as an electron beam, or by increasing the number of passes before a radiation source.

A deinking method using a cellulase which enables the load upon the environment to be reduced; and an evaluation method whereby a cellulase effective in deinking and the effective addition level of the cellulase can be appropriately determined. By proposing pulp-swelling activity (PSA) that elevates the water-retention value of pulp after pulp is reacted with cellulase, it becomes possible to select an enzyme that is effective in cellulase-deinking treatment without lowering the paper strength and to determine the effective enzyme dosage. Namely, a method of deinking waste paper is provided wherein the selection of an effective cellulase and the optimization of the enzyme dosage with the use of PSA as an indication make it possible to minimize the cellulase addition level and lessen the amount of the deinking agent.

The present invention discloses salts of a Compound 1:useful in the prophylaxis and / or treatment of inflammatory conditions, autoimmune diseases, proliferative diseases, allergy, transplant rejection, diseases involving degradation and / or disruption of cartilage homeostasis, congenital cartilage malformations, and / or diseases associated with hypersecretion of IL6 or interferons.

The invention discloses a shielding structure, a shielding assembly and a sodium-cooled fast reactor. The shielding structure comprises a plurality of circles of shielding pieces arranged in the radial direction of the shielding structure, wherein each circle of shielding piece is composed of a plurality of graphite shielding rods forming a circle in a surrounding mode, each graphite shielding rod is formed by splicing a plurality of graphite rods in the axial direction, and the splicing seam positions of the graphite shielding rods arranged in the radial direction of the shielding structure are not completely the same. According to the technical scheme, part of neutrons escaping outwards from the abutted seam position of the graphite rod can be reduced, and the dosage level of the sodium-cooled fast reactor body is reduced.

This invention provides a range of translatable messenger UNA (mUNA) molecules. The mUNA molecules can be translated in vitro and in vivo to provide an active polypeptide or protein, or to provide an immunization agent or vaccine component. The mUNA molecules can be used as an active agent to express an active polypeptide or protein in cells or subjects. Among other things, the mUNA molecules are useful in methods for treating rare diseases.